Jaguar Health Inc. announced that its wholly-owned subsidiary, Napo Pharmaceuticals, has entered into a U.S. licensing agreement with an affiliate of Future Pak, LLC. Under the agreement, Future Pak will become the exclusive U.S. marketer for Mytesi (crofelemer), Jaguar's FDA-approved drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, a crofelemer prescription drug for the treatment of chemotherapy-induced diarrhea in dogs. Jaguar will receive an $18 million upfront payment—$16 million at deal closing and $2 million upon completion of post-closing conditions—as well as up to $20 million in milestone and other future payments. Jaguar will continue to manufacture both products for Future Pak. The agreement also gives Jaguar a 12-month right to reacquire the product rights under certain regulatory conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-014231), on January 15, 2026, and is solely responsible for the information contained therein.